Programmable metal-based immuno-photocatalytic nanoparticles for precision activation of anti-tumor immunity.

In spite of the introduction of cancer immunotherapy for improving tumor suppression, the modality of this revolutionary treatment has faced a number of challenges because of immune evasion, poor tumor immunogenicity, and resistance in solid tumors. To address these challenges, immuno-photocatalytic nanoparticles have been engineered to enable spatiotemporal activation of antitumor immunity by integrating phototherapy with immune modulation. These multifunctional nanoplatforms utilize photo- or ultrasound-responsive cores to generate reactive oxygen species (ROS), stimulate immunogenic cell death (ICD) and enhance the release of tumor-associated antigens. Simultaneously, these platforms allow for the co-delivery of immune checkpoint inhibitors and adjuvants to remodel the tumor microenvironment (TME), enhance dendritic cell maturation, and stimulate cytotoxic T lymphocyte activation. Advanced materials, such as titanium dioxide, copper sulfide, and manganese-based nanostructures, are functionalized with targeting ligands, biodegradable coatings, and diagnostic agents to improve selectivity, circulation time, and imaging capabilities. These nanoparticles also utilize tumor-specific features, such as acidic pH and hypoxia, to trigger controlled drug release and activate various synergistic pathways such as pyroptosis, ferroptosis, and cuproptosis. Preclinical models have shown their substantial effects on tumor suppression, immune activation, and prevention of metastasis with minimal systemic toxicity. Clinically, these nanoplatforms possess a significant potential in overcoming current therapeutic barriers to enable the minimally invasive and highly specific treatment of immunologically resistant tumors. Clinical translation depends on a number of factors including biosafety, large-scale production and regulatory compliance. Immuno-photocatalytic nanomedicine represents a versatile, programmable approach that can be adopted to advance personalized long-term cancer immunotherapy.